AXSM
Axsome Therapeutics Inc
$
100.410
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
101.410
Open
100.820
VWAP
--
Vol
563.83K
Mkt Cap
4.94B
Low
99.700
Amount
--
EV/EBITDA(TTM)
--
Total Shares
47.50M
EV
4.83B
EV/OCF(TTM)
--
P/S(TTM)
11.22
Axsome Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines for people living with central nervous system (CNS) conditions. The Company's commercial products include Auvelity, Sunosi and Symbravo. It is also advancing a diversified, late-stage pipeline of product candidates for serious neurological and psychiatric conditions, which include AXS-05, Solriamfetol, AXS-12 and AXS-14. Auvelity (dextromethorphan-bupropion) is an oral, N-methyl-D-aspartate (NMDA) receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder (MDD). Sunosi (solriamfetol) is an oral medication indicated for the treatment of excessive daytime sleepiness (EDS), in patients with narcolepsy or obstructive sleep apnea. Symbravo (meloxicam and rizatriptan, 20 mg/10mg tablets) is an oral, single-dose medicine approved for the acute treatment of migraine with or without aura in adults.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
138.41M
+58.78%
-1.067
-36.14%
159.76M
+52.49%
-0.830
-38.06%
183.94M
+54.87%
-0.569
-63.07%
Estimates Revision
The market is revising Downward the revenue expectations for Axsome Therapeutics, Inc. (AXSM) for FY2025, with the revenue forecasts being adjusted by -0.93% over the past three months. During the same period, the stock price has changed by -10.58%.
Revenue Estimates for FY2025
Revise Downward
-0.93%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+7.48%
In Past 3 Month
Stock Price
Go Down
-10.58%
In Past 3 Month
15 Analyst Rating
76.36% Upside
Wall Street analysts forecast AXSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXSM is 177.08 USD with a low forecast of 148.00 USD and a high forecast of 210.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Buy
0 Hold
0 Sell
Strong Buy
76.36% Upside
Current: 100.410
Low
148.00
Averages
177.08
High
210.00
76.36% Upside
Current: 100.410
Low
148.00
Averages
177.08
High
210.00
Morgan Stanley
Overweight
initiated
$190
2025-07-03
Reason
Morgan Stanley
Price Target
$190
2025-07-03
initiated
Overweight
Reason
Morgan Stanley assumed coverage of Axsome Therapeutics with an Overweight rating and $190 price target. The firm sees an on-time supplemental new drug application submission for AXS-05 in Alzheimer's Disease agitation as the base case and is modeling $900M in sales in 2030E. Morgan Stanley is encouraged by the continued launch progress of Auvelity in major depressive disorder and awaits the outcomes of the expanded sales force and additional commercial dynamics, the analyst tells investors in a research note.
RBC Capital
Outperform
maintain
$193 -> $186
2025-06-12
Reason
RBC Capital
Price Target
$193 -> $186
2025-06-12
maintain
Outperform
Reason
RBC Capital lowered the firm's price target on Axsome Therapeutics to $186 from $193 but keeps an Outperform rating on the shares. The firm has met with the management to discuss the recent announcement that Axsome's Symbravo is commercially available, the analyst tells investors in a research note. While RBC sees a "relatively modest" contribution to 2025 revenues from the migraine franchise and notes that the fibromyalgia RTF - Refusal to File - letter was disappointing, it also believes that the key drivers of the stock's investment story remain Auvelity uptake in MDD - Major Depressive Disorder - and the Alzheimer's agitation opportunity, the firm added.
Oppenheimer
Matthew Hershenhorn
Outperform
initiated
$185
2025-06-03
Reason
Oppenheimer
Matthew Hershenhorn
Price Target
$185
2025-06-03
initiated
Outperform
Reason
Oppenheimer analyst Matthew Hershenhorn initiated coverage of Axsome Therapeutics with an Outperform rating and $185 price target. The firm views Axsome as a "uniquely attractive" mid-cap biopharma company in neuroscience, based on "multiple differentiating advantages." The company offers accelerating revenue growth with three approved products, a broad pipeline including label expansion opportunities and late-stage assets, which remain underappreciated by the consensus, and several upcoming catalysts that could unlock additional value, the analyst tells investors in a research note. Opco views 2025 and 2026 as a "transformational period" for Axsome, saying the company's sales growth and synergies could drive profitability in 2026.
Jefferies
Andrew Tsai
Strong Buy
Initiates
$200
2025-04-07
Reason
Jefferies
Andrew Tsai
Price Target
$200
2025-04-07
Initiates
Strong Buy
Reason
Jefferies initiated coverage of Axsome Therapeutics with a Buy rating and $200 price target. The company currently markets three central nervous system products, with two more to follow potentially in 2025 and 2026, the analyst tells investors in a research note. The firm thinks Auvelity for depression could generate $1.5B-$2B in peak sales, which on a three-times multiple implies a $4.5B-$6.0B valuation. This makes the rest of Axsome's pipeline "mostly call options," contends Jefferies. It is also 75% confident Auvelity will be approved in 2026 for Alzheimer's agitation, driving the next leg of the company's growth.
HC Wainwright & Co.
Raghuram Selvaraju
Strong Buy
Reiterates
$200
2025-04-03
Reason
HC Wainwright & Co.
Raghuram Selvaraju
Price Target
$200
2025-04-03
Reiterates
Strong Buy
Reason
Needham
Ami Fadia
Strong Buy
Reiterates
$153
2025-04-01
Reason
Needham
Ami Fadia
Price Target
$153
2025-04-01
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Axsome Therapeutics Inc (AXSM.O) is -35.80, compared to its 5-year average forward P/E of -18.14. For a more detailed relative valuation and DCF analysis to assess Axsome Therapeutics Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-18.14
Current PE
-35.80
Overvalued PE
-9.98
Undervalued PE
-26.31
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-29.48
Current EV/EBITDA
-64.81
Overvalued EV/EBITDA
1.61
Undervalued EV/EBITDA
-60.56
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
1662.08
Current PS
7.52
Overvalued PS
7884.44
Undervalued PS
-4560.27
Financials
Annual
Quarterly
FY2025Q1
YoY :
+61.95%
121.46M
Total Revenue
FY2025Q1
YoY :
-15.89%
-57.77M
Operating Profit
FY2025Q1
YoY :
-13.08%
-59.41M
Net Income after Tax
FY2025Q1
YoY :
-15.28%
-1.22
EPS - Diluted
FY2025Q1
YoY :
-18.39%
-43.71M
Free Cash Flow
FY2025Q1
YoY :
+1.30%
90.65
Gross Profit Margin - %
FY2025Q1
YoY :
-64.29%
-27.50
FCF Margin - %
FY2025Q1
YoY :
-46.34%
-48.91
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.8M
USD
11
3-6
Months
0.0
USD
0
6-9
Months
1.9M
USD
2
0-12
Months
1.0M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
1.8M
Volume
4
6-9
Months
2.3M
Volume
7
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
3
408.3K
Volume
Months
6-9
3
924.3K
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
11.8M
USD
11
3-6
Months
0.0
USD
0
6-9
Months
1.9M
USD
2
0-12
Months
1.0M
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
AXSM News & Events
Events Timeline
2025-06-20 (ET)
2025-06-20
07:06:22
Axsome Therapeutics participates in Alzheimer's, Brain Health Awareness Month
2025-06-10 (ET)
2025-06-10
07:07:06
Axsome Therapeutics announces availability of SYMBRAVO in U.S.
2025-06-09 (ET)
2025-06-09
12:58:42
Axsome's AXS-14 gets regulatory setback with RTF, says Morgan Stanley
Sign Up For More Events
Sign Up For More Events
News
1.0
07-21NewsfilterAxsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline
1.0
07-07NewsfilterAxsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21
6.0
07-06Yahoo FinanceMorgan Stanley Assumes Coverage of Axsome Therapeutics (AXSM) with an Overweight Rating
Sign Up For More News
People Also Watch
BC
Brunswick Corp
61.190
USD
+1.46%
POR
Portland General Electric Co
41.290
USD
+0.83%
RDNT
RadNet Inc
56.540
USD
-2.23%
ASAN
Asana Inc
15.210
USD
+1.20%
SLAB
Silicon Laboratories Inc
137.120
USD
+0.67%
IPAR
Interparfums Inc
122.930
USD
-1.73%
ZETA
Zeta Global Holdings Corp
15.480
USD
-3.55%
FTDR
Frontdoor Inc
58.380
USD
-0.21%
SKYW
SkyWest Inc
116.630
USD
-0.76%
PECO
Phillips Edison & Co Inc
35.110
USD
+2.57%
FAQ
What is Axsome Therapeutics Inc (AXSM) stock price today?
The current price of AXSM is 100.41 USD — it has increased 0.02 % in the last trading day.
What is Axsome Therapeutics Inc (AXSM)'s business?
What is the price predicton of AXSM Stock?
What is Axsome Therapeutics Inc (AXSM)'s revenue for the last quarter?
What is Axsome Therapeutics Inc (AXSM)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Axsome Therapeutics Inc (AXSM)'s fundamentals?
How many employees does Axsome Therapeutics Inc (AXSM). have?